IP Library Granted Patent US 9,084,823
Granted Patent B2
US 9,084,823 · App. 13/086,479 · Granted Jul 21, 2015

Formulation for retinoid-containing soft gelatin capsules

Inventors: Günter Ditzinger (Freiburg, DE); Bernhard Gabriel (Oberuzwil, CH); Anne-Hortense Schmitt-Hoffmann (Basel, CH); Lutz Wevelsiep (Lörrach, DE)
Assignee: Glaxo Group Limited
A61K47/46A61K9/4858A61K31/07A61K31/203
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,084,823
App. No.
13/086,479
Granted
Jul 21, 2015
Kind
B2
Abstract

A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated natural vegetable oil and medium chain triglycerides. Optionally, the new formulation also comprises a natural wax. In a particularly preferred embodiment, the soft gelatin capsule comprises pig gelatin in the capsule shell in combination with the above fill mass.

Claims (15)

1. A pharmaceutical formulation for retinoids comprising a soft gelatin capsule filled with a fill mass comprising 9-cis retinoic acid or pharmaceutically acceptable salts thereof as an active ingredient, from about 50 to 80 percent by weight of a natural vegetable oil, from about 15 to 35 percent by weight of a partially hydrogenated natural vegetable oil, from about 3 to 20 percent by weight of a medium chain triglyceride selected from triglycerides of saturated fatty acids containing 8 to 10 carbon atoms, and from about 1 to 10 percent by weight of natural wax.

2. The pharmaceutical formulation of claim 1 , wherein the fill mass further comprises an antioxidant.

3. The pharmaceutical formulation of claims 1 , wherein the natural vegetable oil is selected from soybean oil, corn oil, sunflower oil, rape seed oil, linseed oil, sesame oil, olive oil, coconut oil, peanut oil, safflower oil, castor oil and cottonseed or mixtures of two or more of these oils.

4. The pharmaceutical formulation of claim 3 , wherein the natural vegetable oil is soybean oil.

5. The pharmaceutical formulation of claim 1 , wherein the natural wax is yellow wax.

6. The pharmaceutical formulation of claim 2 , wherein the antioxidant is selected from DL-α-tocopherol butylhydroxy toluene (BHT) and butylhydroxy anisole (BHA).

7. The pharmaceutical formulation of claim 1 , wherein the capsule shell comprises gelatin, one or more plasticizers and water.

8. The pharmaceutical formulation of claim 7 , wherein the plasticizer is selected from the group consisting of glycerol, sorbitol, propylene glycol, and mixtures of these components.

9. The pharmaceutical formulation of claim 8 , wherein the plasticizer comprises a mixture of glycerol and sorbitol.

10. The pharmaceutical formulation of claim 7 , wherein the gelatin is pig gelatin.

11. The pharmaceutical formulation of claim 7 , wherein the gelatin is bovine gelatin.

12. The pharmaceutical formulation of claim 1 wherein the partially hydrogenated natural vegetable oil is selected from soybean oil, corn oil, sunflower oil, rape seed oil, linseed oil, sesame oil, olive oil, coconut oil, peanut oil, safflower oil, castor oil or cottonseed oil, or mixture of two or more of these oils.

13. The pharmaceutical formulation of claim 12 wherein the partially hydrogenated natural vegetable oil is soybean oil.

14. The pharmaceutical formulation of claim 1 wherein the triglyceride is caprylic acid, capric acid, or a mixture of caprylic acid and capric acid.

15. The pharmaceutical formulation of claim 1 , wherein the fill mass comprises from about 60 to 70 percent by weight natural vegetable oil, from about 20 to 30percent by weight of partially hydrogenated vegetable oil, from about 6 to 12 percent by weight of the medium chain triglyceride, and from about 3 to 6 percent by weight of natural wax.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2020
From: BASILEA PHARMACEUTICA INTERNATIONAL LTD
To: GALEPHAR PHARMACEUTICAL RESEARCH, INC.
Reel/Frame 054358/0326 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2017
From: GLAXO GROUP LIMITED
To: BASILEA PHARMACEUTICA INTERNATIONAL LTD.
Reel/Frame 043414/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2015
From: DITZINGER, GUNTER; GABRIEL, BERNHARD; SCHMITT-HOFFMANN, ANNE-HORTENSE; WEVELSIEP, LUTZ
To: BASILEA PHARMACEUTICA AG
Reel/Frame 035814/0414 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2015
From: BASILEA PHARMACEUTICA INTERNATIONAL LTD.
To: GLAXO GROUP LIMITED
Reel/Frame 035875/0600 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2012
From: BASILEA PHARMACEUTICA INTERNATIONAL LTD
To: GLAXO GROUP LIMITED
Reel/Frame 029277/0193 →
Priority Claims (1)
EP 03405788 · Mar 11, 2003 · regional
Continuity (2)
Continuation 10958704 · Oct 5, 2004
Related Publication 20110212170A1 · Sep 1, 2011